Dexmedetomidine or Lidocaine for Lessening the Hemodynamic Responses to Laryngoscopy and Intubation

Comparing Intravenous Versus Nebulized Either Lidocaine or Dexmedetomidine for Attenuation of the Hemodynamic Responses to Laryngoscopy and Intubation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05941767

Enrollment

100

Registered

2023-07-12

Start date

2023-07-12

Completion date

2024-01-03

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia Intubation Complication

Keywords

Dexmedetomidine, Lidocaine

Brief summary

Laryngoscopy, tracheal intubation, surgical stimulation, and extubation unleash remarkable sympathetic activity and are associated with transient but significant hemodynamic changes. The need to blunt these noxious responses effectively has led to using several techniques and pharmacological agents, local anesthetics, beta-adrenergic-blockers, calcium channel antagonists, and opioids with varied success. This study aims to evaluate the effect of nebulized and intravenous either dexmedetomidine or lidocaine for attenuating the hemodynamic responses to laryngoscopy and intubation.

Detailed description

Hemodynamic responses to laryngoscopy and intubation are a significant concern for the anesthesiologist. Laryngoscopy, tracheal intubation, surgical stimulation, and extubation unleash remarkable sympathetic activity and are associated with transient but significant hemodynamic changes. These hemodynamic derangements can be lethal in patients with multiple comorbidities. The need to blunt these noxious responses effectively has led to using several techniques and pharmacological agents, local anesthetics, beta-adrenergic-blockers, calcium channel antagonists, and opioids with varied success. This study aims to evaluate the effect of nebulized and intravenous either dexmedetomidine or lidocaine for attenuating the hemodynamic responses to laryngoscopy and intubation.

Interventions

DRUGDexmedetomidine nebulization

The patient will receive nebulized dexmedetomidine via face mask nebulizer 10 minutes before induction of general anesthesia.

DRUGLidocaine nebulization

The patient will receive nebulized lidocaine 4% (3 mg /kg) 10 minutes before induction of general anesthesia.

DRUGDexmedetomidine IV

The patient will receive intravenous infusion via a syringe pump of dexmedetomidine (1 ml= 4mcg) started at a dose of 1 mcg/kg 20 minutes before induction of general anesthesia.

DRUGLidocaine IV

The patient will receive 1.5 mg/kg lidocaine 2% (1 ml = 20mg) completed to 10 ml with normal saline 0.9% intravenous 90 seconds before induction of general anesthesia.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* The American Society of Anesthesiologists (ASA) physical status I & II. BMI: ((≤ 35 kg/m2)). The patients are to be scheduled to undergo elective surgery under general anesthesia. Mallampati grade I, II

Exclusion criteria

* Uncooperative patient. History of allergy to study drugs. Hemodynamically unstable patient. Renal or hepatic dysfunction or hypertensive patients.

Design outcomes

Primary

Measure	Time frame	Description
Change in serum cortisol levels.	Measurement will be done 45 minutes preoperative and 10 minutes after endotracheal intubation.	Base line blood sample will be drawn 45 minutes preoperative and 10 minutes post intubation for cortisol level measurements.
Change in mean arterial blood pressure (MAP) in mmHg.	Measurement will be done 10 minutes before induction and at 1,3,5,7 and 10 minutes after endotracheal intubation.	Mean arterial pressure (MAP) will be recorded 10 minutes before induction and at 1,3,5,7 and10 minutes after endotracheal intubation.
Change in heart rate (HR) per minute.	Measurement will be done 10 minutes before induction and at 1,3,5,7 and 10 minutes after endotracheal intubation.	Heart rate (HR) will be recorded 10 minutes before induction and at 1,3,5,7 and10 minutes after endotracheal intubation.
Change in systolic blood pressure (SBP) in mmHg.	Measurement will be done 10 minutes before induction and at 1,3,5,7 and 10 minutes after endotracheal intubation.	Systolic blood pressure (SBP)will be recorded 10 minutes before induction and at 1,3,5,7 and10 minutes after endotracheal intubation.
Change in diastolic blood pressure (DBP) in mmHg.	Measurement will be done 10 minutes before induction and at 1,3,5,7 and10 minutes after endotracheal intubation.	Diastolic blood pressure (SBP)will be recorded 10 minutes before induction and at 1,3,5,7 and 10 minutes after endotracheal intubation.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026